GlassScriptPhysician profile
Lawrence H Wells
NPI 1497753206
$1,697.99
in general payments reported to CMS, 2019-2025
33 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $296 · 2021: $25.08 · 2022: $354 · 2023: $215 · 2024: $96.70 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $433.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $238.27 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.97 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $85.28 | 2019-2022 | |
| Dexcom, INC. | $85.13 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $77.74 | 2019-2022 | |
| Astellas Pharma US INC | $77.61 | 2019-2023 | Myrbetriq |
| Gilead Sciences, INC. | $74.77 | 2020 | |
| Mylan Specialty L.P. | $58.93 | 2019-2020 | |
| Abbott Laboratories | $58.13 | 2023-2024 | Proclaim, Eterna |
| Amarin Pharma, INC. | $54.87 | 2019-2022 | |
| Sanofi Pasteur INC. | $51.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $44.56 | 2019 | |
| Glaxosmithkline, LLC. | $44.20 | 2019-2023 | Trelegy Ellipta |
| Abbvie INC. | $43.71 | 2022-2023 | Vraylar |
| Amgen INC. | $42.29 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.48 | 2022-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $40.06 | 2021-2022 | |
| Boston Scientific Corporation | $35.15 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.01 | 2019-2020 | |
| Vertiflex, INC. | $31.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.53 | 2022 | |
| Edwards Lifesciences Corporation | $28.34 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Merck Sharp & Dohme LLC | $24.50 | 2019-2020 | |
| Organogenesis INC. | $23.47 | 2025 | Affinity |
| Bayer Healthcare Pharmaceuticals INC. | $21.05 | 2022 | |
| Shield Therapeutics INC | $20.94 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $17.60 | 2019 | |
| Cook Medical LLC | $16.46 | 2024 | Micropuncture |
| Lilly USA, LLC | $15.06 | 2022 | |
| Cranial Technologies, INC | $14.86 | 2020 | |
| Novo Nordisk INC | $14.79 | 2022 | |
| Horizon Therapeutics Plc | $14.44 | 2019 | |
| Allergan, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Wells listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.